# EJR-167 — 2026-08-14 P1 Revalidation Session Closure

## Session scope

P0/P1 continuation following the HERMUZ handoff and priority order.

## Evidence closed this session

### Integration failure
`INT-FAIL-002` is now evidence-backed:

- GitHub Actions run: `31772269633`
- Integration job: `94681554508`
- Merge snapshot: `c9abe45186636c9e707f969ea45c995b702c9655`
- Command: `python -m pytest -q`
- Result: `78 passed, 2 failed`

The two failures are deterministic semantic contract mismatches:

1. CORE-000 metadata format: test expects `Document ID: CORE-000`; canonical file uses separate metadata lines.
2. REP-013 canonicalization: PR #3 merge snapshot predates the current-main Specifications path.

Neither failure is evidence of a Runtime execution defect or CI infrastructure failure.

## Controlled mutation

Created PR #4 from the latest current `main`:

`ci/runtime-prototype-reconciled-20260814-v3`

Head: `8f7594decc80a45bdc22fab3afdcefd6a4a2b7dd`

Scope is limited to removing the unreachable `REJECTED` state/branch from the Runtime Prototype authorization state model. Integration tests were not modified.

PR #4 CI result at closure: **QUEUED / NOT YET TESTED**.

## Matrix evidence

Created REP-020 revalidation appendix:
`Repository/REP-020_REVALIDATION_APPENDIX_2026-08-14_P1.md`

It records performed/not-performed tests and the new integration findings without replacing the main REP-020 matrix content.

## Not closed

- Main REP-020 content has not yet been structurally merged with the appendix; this is intentionally left as the next controlled documentation mutation rather than overwriting the matrix blindly.
- Baseline 3.2.1 vs 3.3.0 remains unresolved.
- Executable RUN-010 → ENG-006 → SRV-009 proof remains open.
- Exhaustive duplicate-ID audit remains PARTIAL.
- PR #4 CI and post-PR4 integration/prototype regression remain pending.

## Integrity decision

**INTEGRITY HOLD**

No PASS promotion. No merge performed.

## Session closure rule

This session is closed after the latest repository modification. Any subsequent mutation must begin a new evidence checkpoint and update REP-020 evidence accordingly.
